Tesamorelin vs Ipamorelin

Tesamorelin (TH9507) is a 44-amino acid synthetic analog of human GHRH(1-44), stabilized by the addition of a trans-2-hexenoic acid moiety at the N-terminus. This modification protects the molecule from degradation by dipeptidyl peptidase IV (DPP-IV) while preserving full agonist activity at the GHRH receptor. Developed by Theratechnologies, Tesamorelin received FDA approval in 2010 as Egrifta for the reduction of excess visceral abdominal fat in HIV-infected patients with antiretroviral-associated lipodystrophy. That makes it one of the very few GH secretagogues with Phase 3 randomized controlled trial data and regulatory approval. The key mechanistic feature distinguishing Tesamorelin from many GH secretagogues is its preservation of physiological feedback regulation. Because it acts through the GHRH receptor alone, without bypassing the somatostatin negative-feedback loop, GH release under Tesamorelin stimulation remains subject to the brain's normal pulsatile regulation. Documented effects include significant reductions in visceral adipose tissue volume as measured by CT in lipodystrophy trials, alongside IGF-1 elevation within physiological range. The compound's body composition research profile makes it relevant to metabolic research beyond its original lipodystrophy indication, and it appears in published studies examining GH secretagogue effects on lean mass, triglyceride levels, and insulin sensitivity.

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide growth hormone-releasing peptide developed by Novo Nordisk researchers in the late 1990s. It was designed for selectivity: among all GHRPs studied, Ipamorelin produces the most isolated GH pulse amplification with the least co-stimulation of cortisol, ACTH, and prolactin. This selectivity profile has made it one of the most studied reference GHRPs in the preclinical literature. Ipamorelin acts through the GHS-R1a (ghrelin receptor), the same receptor that binds acylated ghrelin. This pathway is complementary to the GHRH receptor pathway, and the two together produce additive to synergistic GH release. That's why Ipamorelin is almost always studied in combination with CJC-1295 in research protocols examining maximized GH secretagogue activity. CJC-1295/Ipamorelin blends are the standard formulation in research settings. In animal studies, Ipamorelin has been associated with elevated IGF-1 and changes in body composition metrics consistent with GH pathway activation, without the ACTH and cortisol co-elevation seen with older GHRPs like GHRP-6. Its short half-life (~2 hours) supports use in pulsatile GH secretion research designs where researchers want discrete, controllable stimulation windows.